Please login to the form below

Not currently logged in
Email:
Password:

Medicxi appoints former GSK chair Moncef Slaoui

He joins the life science investment firm as a partner

Moncef SlaouiLondon, UK-based life science investment group Medicxi has appointed former GSK chairman of pharmaceutical R&D, vaccines Dr Moncef Slaoui as its new partner.

Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.

He previously spent 28 years at GSK, and retired earlier this year.

He said: “Having developed a strong relationship with the Medicxi founders over many years, it is an exciting time to join the team, with funds available to invest not only in early stage assets but also to building innovative companies through clinical development and market entry.

“I am looking forward to making an active contribution to selecting and leading investments, and to supporting ambitious entrepreneurs to develop medicines hat ultimately make a difference to patients.”

His new role will see him at the helm of sponsoring and supporting investments, undertaking due diligence and valuations for the group’s venture fund and growth fund, and he will support investee companies in their development.

Michéle Ollier, co-founder and partner at Medicxi, said: “Moncef has made a tremendous contribution through his role on our SABs and we look forward to his continued energetic and insightful contribution as a partner at Medicxi.”

2nd October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Top Pharma News

TopPharmaNews.com is a global pharma magazine dedicated to delivering fresh news to society. The team at the TopPharmaNews.com cater non-biased,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics